Information Provided By: 
Fly News Breaks for May 15, 2017
KPTI
May 15, 2017 | 09:10 EDT
Cantor analyst Mara Goldstein started coverage of Karyopharm with an $18 price target and an Overweight rating. She is upbeat on the clinical performance of its lead drug candidate, selinexor. The analyst says that the drug "has broad applications in cancer, as well as potentially other areas such as infectious and inflammatory disease."
News For KPTI From the Last 2 Days
There are no results for your query KPTI
